BofA raised the firm’s price target on KalVista (KALV) to $37 from $22 and keeps a Buy rating on the shares after the company announced the approval of Ekterly for on-demand treatment of hereditary angioedema attacks with a broad label and no restrictions on type of HAE attack or background LTP usage for patients 12 and older. The firm, which says the approval was in-line with its expectations and it is “encouraged by the broad label,” remains “bullish” on Ekterly’s differentiation as the only oral on-demand treatment on the market, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KALV:
- KalVista price target raised to $27 from $19 at Citizens JMP
- KalVista price target raised to $20 from $18 at Leerink
- Buy Rating for KalVista Pharmaceuticals Driven by FDA Approval and Strategic Market Entry of Ekterly
- KalVista price target raised to $40 from $32 at Jefferies
- Musk to launch new political party, Trump threatens BRICS tariff: Morning Buzz